Therapeutic efficacy and safety of telmisartan in patients with non-alcoholic fatty liver disease (NAFLD) and hypertension: exploratory research
Not Applicable
Recruiting
- Conditions
- on-alcoholic fatty liver disease and hypertension
- Registration Number
- JPRN-UMIN000020537
- Lead Sponsor
- Department of General Internal Medicine, Kyushu University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
(1) Treatment histody of ARB, ACE inhibitor, renin inhibitor, or thiazolidine (2) History of hepatic disease, such as chronic hepatitis C or concurrent active hepatitis B (serum positive for hepatitis B surface antigen), autoimmune hepatitis, or primary biliary cirrhosis (PBC) (3) Secondary hypertension (4) History of allergy for telmisartan (5) Pregnancy or lactation in women (6) Inadequacy for this therapy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method